microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3

References

• Tang YH, He GL, Huang SZ, et al. The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma. Mol Oncol. 2019;13(5):1296–1310.
   PubMed Web of Science ®Google Scholar
• Teng CF, Wu HC, Su IJ, et al. Hepatitis B virus Pre-S mutants as biomarkers and targets for the development and recurrence of hepatocellular carcinoma. Viruses. 2020;12(9). DOI:10.3390/v12090945
   Web of Science ®Google Scholar
• Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1039–1052.
   PubMed Web of Science ®Google Scholar
• Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol. 2018;69(2):345–352.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim B, Kim HJ, et al. Liver stiffness measured by MR elastography is a predictor of early HCC recurrence after treatment. Eur Radiol. 2020;30(8):4182–4192.
   PubMed Web of Science ®Google Scholar
• Gao X, Zhan M, Wang L, et al. Timing of DAA initiation after curative treatment and its relationship with the recurrence of HCV-related HCC. J Hepatocell Carcinoma. 2020;7:347–360.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang Z, Zhang W, et al. MicroRNAs play an essential role in autophagy regulation in various disease phenotypes. Biofactors. 2019;45(6):844–856.
   PubMed Web of Science ®Google Scholar
• Galagali H, Kim JK. The multifaceted roles of microRNAs in differentiation. Curr Opin Cell Biol. 2020;67:118–140.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen H, Bai J, et al. MicroRNA: an important regulator in acute myeloid leukemia. Cell Biol Int. 2017;41(9):936–945.
   PubMed Web of Science ®Google Scholar
• Norouzi M, Yasamineh S, Montazeri M, et al. Recent advances on nanomaterials-based fluorimetric approaches for microRNAs detection. Mater Sci Eng C Mater Biol Appl. 2019;104:110007.
   PubMed Web of Science ®Google Scholar
• Emamgolizadeh Gurt Tapeh B, Mosayyebi B, Samei M, et al. microRNAs involved in T-cell development, selection, activation, and hemostasis. J Cell Physiol. 2020;235(11):8461–8471.
   PubMed Web of Science ®Google Scholar
• Emming S, Chirichella M, Monticelli S. MicroRNAs as modulators of T cell functions in cancer. Cancer Lett. 2018;430:172–178.
   PubMed Web of Science ®Google Scholar
• Shirjang S, Mansoori B, Asghari S, et al. MicroRNAs in cancer cell death pathways: apoptosis and necroptosis. Free Radic Biol Med. 2019;139:1–15.
   PubMed Web of Science ®Google Scholar
• Staicu CE, Predescu DV, Rusu CM, et al. Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: a Short Overview. Cells. 2020;9(1). DOI:10.3390/cells9010169
   PubMed Web of Science ®Google Scholar
• Anauate AC, Leal MF, Calcagno DQ, et al. The complex network between MYC oncogene and microRNAs in gastric cancer: an overview. Int J Mol Sci. 2020;21(5). DOI:10.3390/ijms21051782
   PubMed Web of Science ®Google Scholar
• Gupta M, Akhtar J, Sarwat M. MicroRNAs: regulators of immunological reactions in hepatocellular carcinoma. Semin Cell Dev Biol. 2021. DOI:10.1016/j.semcdb.2021.05.025
   Web of Science ®Google Scholar
• Zhang L, Wu ZA. MicroRNA-378a-3p downregulation as a novel biomarker with poor clinical outcomes in cervical cancer. Biomed Environ Sci. 2021;34(3):213–221.
   PubMed Web of Science ®Google Scholar
• Mao Y, Li W, Hua B, et al. Circular RNA_PDHX promotes the proliferation and invasion of prostate cancer by sponging MiR-378a-3p. Front Cell Dev Biol. 2020;8:602707.
   PubMed Web of Science ®Google Scholar
• Rong D, Dong Q, Qu H, et al. m(6)A-induced LINC00958 promotes breast cancer tumorigenesis via the miR-378a-3p/YY1 axis. Cell Death Discov. 2021;7(1):27.
   PubMed Web of Science ®Google Scholar
• Qian F, Wang J, Wang Y, et al. MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: computational screening with experimental validation. Clin Transl Med. 2021;11(2):e307.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Thieringer FR, Maass T, Anthon B, et al. Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma. Mol Carcinog. 2012;51(6):439–448.
   PubMed Web of Science ®Google Scholar
• Lu L, Zhang Q, Wu K, et al. Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-kappaB signal cascade. Cancer Lett. 2015;356(2 Pt B):470–478.
   PubMed Web of Science ®Google Scholar
• Ordonez R, Carbajo-Pescador S, Prieto-Dominguez N, et al. Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J Pineal Res. 2014;56(1):20–30.
   PubMed Web of Science ®Google Scholar
• Yang Q, Zhao S, Shi Z, et al. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. J Exp Clin Cancer Res. 2021;40(1):120.
   PubMed Web of Science ®Google Scholar
• Huang H, Bu YZ, Zhang XY, et al. LINC01433 promotes hepatocellular carcinoma progression via modulating the miR-1301/STAT3 axis. J Cell Physiol. 2019;234(5):6116–6124.
   PubMed Web of Science ®Google Scholar
• Zhu M, Shi X, Gong Z, et al. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner. Pharmacol Res. 2020;158:104868.
   PubMed Web of Science ®Google Scholar
• Wu S, Ye S, Lin X, et al. Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling. Cancer Lett. 2021;499:175–187.
   PubMed Web of Science ®Google Scholar
• Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol. 2012;19(6):586–593.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu LL, Wen D, et al. MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming. J Hematol Oncol. 2020;13(1):12.
   PubMed Web of Science ®Google Scholar
• Ke MY, Xu T, Fang Y, et al. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation. Cancer Lett. 2021;513:14–25.
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu Y, Yan Z, et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J Immunother Cancer. 2020;8(1). DOI:10.1136/jitc-2019-000285
   Web of Science ®Google Scholar
• Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist. 2018;23(12):1407–e136.
   PubMed Web of Science ®Google Scholar
• Sun TX, Li MY, Zhang ZH, et al. Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity. Phytother Res. 2021. DOI:10.1002/ptr.7103
   Web of Science ®Google Scholar
• Verdura S, Cuyas E, Cortada E, et al. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging (Albany NY). 2020;12(1):8–34.
   PubMedGoogle Scholar
• Zhang YF, Zhang ZH, Li MY, et al. Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1alpha in cancer. Phytomedicine. 2021;81:153425.
   PubMed Web of Science ®Google Scholar
• Pena-Asensio J, Calvo H, Torralba M, et al. Anti-PD-1/PD-L1 based combination immunotherapy to boost antigen-specific CD8(+) T cell response in hepatocellular carcinoma. Cancers (Basel). 2021;13(8). DOI:10.3390/cancers13081922
   PubMed Web of Science ®Google Scholar
• Sasaki S, Nishikawa J, Sakai K, et al. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. Gastric Cancer. 2019;22(3):486–496.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Buti S, Bersanelli M, et al. Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. Oncoimmunology. 2020;9(1):1710389.
   PubMed Web of Science ®Google Scholar
• Komura N, Mabuchi S, Shimura K, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer Immunol Immunother. 2020;69(12):2477–2499.
   PubMed Web of Science ®Google Scholar
• Chen L, Yi C, Li W, et al. Inhibition of SPATS2 suppresses proliferation and invasion of hepatocellular carcinoma cells through TRIM44-STAT3 signaling pathway. J Cancer. 2021;12(1):89–98.
   PubMed Web of Science ®Google Scholar
• Xiong D, Jin C, Ye X, et al. TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway. Cancer Sci. 2018;109(10):3080–3092.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012;22(4):327–334.
   PubMed Web of Science ®Google Scholar
• Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109(10):2629–2635.
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Schilling B, Harasymczuk M, et al. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol. 2012;42(7):1876–1885.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538–543.
   PubMed Web of Science ®Google Scholar
• Galeano Nino JL, Tay SS, Tearle JLE, et al. The Lifeact-EGFP mouse is a translationally controlled fluorescent reporter of T cell activation. J Cell Sci. 2020;133(5). DOI:10.1242/jcs.238014
   PubMed Web of Science ®Google Scholar
• Snyder LD, Chan C, Kwon D, et al. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 2016;193(1):78–85.
   PubMed Web of Science ®Google Scholar